Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sutent sunitinib: Phase I/II data

A retrospective review of cardiovascular events in a 75-patient cohort from an open-label, dose-escalation,

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE